benzinga.comNovartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million2 days ago
finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)7 months ago
finance.yahoo.comTriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer8 months ago
finance.yahoo.comWe Think Regulus Resources (CVE:REG) Can Easily Afford To Drive Business Growth9 months ago
finance.yahoo.comCompanies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth9 months ago
finance.yahoo.comRegulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference9 months ago
finance.yahoo.comMaquia Capital Acquisition Corporation Plans to Trade OTC After Delist from Nasdaq9 months ago
CashuNovartis Acquires Regulus Therapeutics for $0.8 Billion to Enhance RNA-Targeted Therapiesabout 14 hours ago